Skip to main content
Appili Therapeutics Inc. logo

Appili Therapeutics Inc. — Investor Relations & Filings

Ticker · APLI TSX Manufacturing
Open in API
Filings indexed 247 across all filing types
Latest filing 2025-05-31 Regulatory Filings
Country CA Canada
Listing TSX APLI

About Appili Therapeutics Inc.

https://appilitherapeutics.com/

Appili Therapeutics Inc. is a biopharmaceutical company focused on the acquisition and development of novel medicines targeting unmet needs across a broad spectrum of infectious diseases and biodefense. The company advances anti-infective therapies to provide solutions for patients and healthcare providers. Its pipeline includes LIKMEZ™ (ATI-1501), a novel oral taste-masked suspension of metronidazole for serious anaerobic and protozoal infections; ATI-1701, a potential first-in-class live-attenuated vaccine for tularemia (a serious biothreat); and ATI-1801, a novel topical antiparasitic product designed to treat disfiguring skin infections.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 1% confidence The document is a Form 51-102F3 Material Change Report filed under Canadian NI 51-102 and posted on SEDAR+. It provides disclosure of a material change (termination of an arrangement agreement, related termination fee, loan extensions) rather than presenting financial results or a management presentation. It is a mandatory regulatory filing and does not fit more specific categories (e.g., earnings release, capital financing update, M&A announcement, etc.), so it defaults to the general Regulatory Filings category (RNS).
2025-05-31 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a press release announcing that Appili Therapeutics has received a termination notice under an existing Arrangement Agreement with Aditxt, Inc. (a typical Canadian-style M&A agreement). It does not present financial results or regulatory disclosures such as earnings, dividends, or proxy solicitations. Rather, it provides an update on a merger/arrangement transaction being terminated and the related termination fee. Therefore, it falls under M&A Activity (Code: TAR).
2025-05-19 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing the publication of a scientific manuscript by Appili Therapeutics. It contains no financial results, no management changes, no shareholder votes, no capital/financing update, and is not a formal regulatory filing such as an annual report, earnings release, or proxy statement. It does not fit any specific filing category and thus falls into the fallback “Regulatory Filings” category (RNS).
2025-05-01 English
News release - English.pdf
Regulatory Filings Classification · 0% confidence The document is a press release announcing that Appili’s CEO will join an Aditxt Weekly Update event. It does not contain earnings figures or Q&A transcript, nor is it an AGM/annual/interim report, audit, investor presentation, or detailed M&A filing. There is no report attached or proxy solicitation. It primarily serves as a general corporate news/announcement to investors. Therefore it falls under the fallback “Regulatory Filings” category.
2025-04-02 English
News release - English.pdf
M&A Activity Classification · 1% confidence The document is a corporate press release announcing both the submission of US government funding proposals and, critically, an update on its going‐private transaction with Aditxt Inc. The going‐private transaction is a planned takeover via a court-approved plan of arrangement, fitting squarely within the M&A Activity category. This is not a straight capital markets financing announcement (no new debt or equity issuance), nor an earnings or periodic report, but rather an M&A update. Therefore, the most appropriate classification is M&A Activity (TAR).
2025-03-18 English
News release - English.pdf
Regulatory Filings
2024-11-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.